[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

[HTML][HTML] Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review

RR He, GL Yue, ML Dong, JQ Wang… - International journal of …, 2024 - mdpi.com
Sepsis is now defined as a life-threatening syndrome of organ dysfunction triggered by a
dysregulated host response to infection, posing significant challenges in critical care. The …

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

PW Horby, G Pessoa-Amorim, L Peto, CE Brightling… - Medrxiv, 2021 - medrxiv.org
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …

[HTML][HTML] RETRACTED: Empowering Low-and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward

M Kanan, M Ramadan, H Haif, B Abdullah, J Mubarak… - Antibiotics, 2023 - mdpi.com
Antibiotic overuse poses a critical global health concern, especially in low-and middle-
income countries (LMICs) where access to quality healthcare and effective regulatory …

Inappropriate antibiotic prescribing and its determinants among outpatient children in 3 low-and middle-income countries: A multicentric community-based cohort …

A Ardillon, L Ramblière, E Kermorvant-Duchemin… - PLoS …, 2023 - journals.plos.org
Background Antibiotic resistance is a global public health issue, particularly in low-and
middle-income countries (LMICs), where antibiotics required to treat resistant infections are …

Future biomarkers for infection and inflammation in rheumatoid arthritis

S Cui, J Qian - Journal of Inflammation Research, 2023 - Taylor & Francis
Rheumatoid arthritis (RA) increases the susceptibility to a variety of infections that are often
difficult to diagnose and can be asymptomatic or symptoms are atypical. Usually, this is a …

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

DJ Dhasmana… - …, 2021 - research-repository.st-andrews.ac …
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Point-of-care C-reactive protein measurement by community health workers safely reduces antimicrobial use among children with respiratory illness in rural Uganda …

EJ Ciccone, D Hu, JS Preisser, CA Cassidy… - PLoS …, 2024 - journals.plos.org
Background Acute respiratory illness (ARI) is one of the most common reasons children
receive antibiotic treatment. Measurement of C-reaction protein (CRP) has been shown to …

Reagent-free anti-fouling electrochemical immunosensor based on AL-BSA/AuNPs/PANI coating for the point-of-care detection of C-reactive protein in plasma and …

TC Lu, YT Lin, WB ** the portable CRP detection technologies that are suitable for point-of-care
(POC) and primary care management is of utmost importance, and advancing the …